MetalloDrugDB - Complete Database Acquisition (300 Compounds)
The world's first patent-pending[1] database of 300 advanced multi-element pharmaceutical compounds spanning 15 therapeutic categories and 43 elements. Includes U.S. Patent Application 19/630,444, full synthesis data, and scientific validation report. Exclusive acquisition opportunity. .
© CRI-ONE. All rights reserved. Patents issued and pending. Unauthorized reproduction of the underlying designs is prohibited.
Extended catalog & full narrative — MetalloDrugDB - Complete Database Acquisition (300 Compounds, Patent Included)
The extended dossier appended from the 2026-08-05 catalog snapshot. Prices in the body copy have been stripped; the live-store price on this page is the authoritative figure. Images have been omitted.
Downloads immediately on checkout — the MetalloDrugDB Complete 2026 bundle (AES-256 encrypted, 4.9 MB). Open with 7-Zip, WinRAR, or macOS Archive Utility. Bundle contains all 300 compound recipes, patent application 19/630,444, four patent drawings, the cross-reference validation report, and 300 per-disease research files. Patent Assignment and other closing documents (Sale Agreement Article 4) transfer separately upon executed contract — contact the seller for the closing process.
MetalloDrugDB™
The World's First Patent-pending[1] Multi-Element Pharmaceutical Compound Database
What You Are Purchasing
The complete MetalloDrugDB — a proprietary database of 300 advanced multi-element coordination complexes designed for pharmaceutical applications. This is the first and only structured database of metal-based therapeutic compounds in existence.
A 2022 study published in Drug Discovery Today confirmed that no public metallodrug database exists anywhere in the pharmaceutical sciences. MetalloDrugDB fills that gap.
By The Numbers
| Metric | Value |
|---|---|
| Total Compounds | 300 |
| Therapeutic Categories | 15 |
| Elements Used | 43 |
| Scientific Cross-Reference Score | 80-87% |
| Databases Cross-Referenced | 10 |
| Patent Status | Filed (U.S. App. No. 19/630,444) |
| Priority Date | March 27, 2026 |
15 Therapeutic Categories
| Cat | Category | Compounds |
|---|---|---|
| A | Antimicrobial | 20 |
| B | Cardiovascular | 20 |
| C | Respiratory | 20 |
| D | Gastrointestinal | 20 |
| E | Analgesic & Anti-inflammatory | 20 |
| F | Endocrine | 20 |
| G | Neurological | 20 |
| H | Dermatological | 20 |
| I | Hematologic | 20 |
| J | Psychiatric | 20 |
| K | Renal & Hepatic | 20 |
| L | Immunological | 20 |
| M | Metabolic | 20 |
| N | Oncologic Support | 20 |
| O | Ophthalmic & Sensory | 20 |
What Makes This Valuable
- No Competition. No metallodrug database exists anywhere. This is the only one.
- Patent Protected. U.S. Patent Application 19/630,444 covers compositions, synthesis methods, and therapeutic applications.
- Scientifically Validated. Cross-referenced against 10 major pharmaceutical databases including PubChem (119M compounds), ChEMBL (2.5M compounds), DrugBank, ClinicalTrials.gov, and more. Validation score: 80-87%.
- Market Context. Cisplatin alone (one platinum compound) generates billions annually and is used in 50-70% of all cancer treatment protocols. This database contains 300 compounds across 43 elements.
- Ready to Use. Complete synthesis parameters, elemental composition tables, molecular weights, and preparation notes for every compound.
What You Receive
- 300 complete compound formulations with full synthesis data
- U.S. Patent Application (assignable to buyer)
- Cross-Reference Validation Report with 30+ scientific citations
- 4 patent-quality technical drawings
- Master index and categorization system
- All source files and digital assets
- Executed Asset Purchase Agreement with Patent Assignment
Who Should Acquire This
- Pharmaceutical companies seeking new drug candidates
- Biotech startups building a compound pipeline
- Research institutions developing metal-based therapeutics programs
- Investment groups acquiring pharmaceutical IP assets
This is an exclusive acquisition. Upon sale, all rights, patent ownership, and database assets transfer to the buyer via executed Asset Purchase Agreement.
Serious inquiries only. NDA available upon request.
Contact: crioneaka@outlook.com
Patent Application: 19/630,444 | Confirmation: 1348
MetalloDrugDB™ — 300 Compounds. 43 Elements. 15 Categories. One Database. First of Its Kind.
Acquisition Path
This product is available through CGB's 4-step acquisition path. The current price is shown in your cart and on the live storefront page.
- Step 1 — Proof of Function: public, each.
- Step 2 — Mathematical Deposition: reading material under mutual NDA.
- Step 3 — Evaluation License: hands-on evaluation under NDA; fee credits toward Step 4.
- Step 4 — Full Acquisition: You are buying the blueprint. And the right to build it. Not to be used any other way.
d3e7bcf75b2195692aa412da8a153963971b6af358f0daa8ecc71fcb4495ae9fMetalloDrugDB - Complete Database Acquisition (300 Compounds)
Publicly online since 2010 · U.S. patent applications since 2012 · inventions offered since 2014. The work of Christopher Gabriel Brown, independently documented.
